Overview QUILT-3.080: NANT Pancreatic Cancer Vaccine Status: Unknown status Trial end date: 2019-12-01 Target enrollment: Participant gender: Summary This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy. Phase: Phase 1/Phase 2 Details Lead Sponsor: ImmunityBio, Inc.NantKwest, Inc.Treatments: Albumin-Bound PaclitaxelAvelumabBevacizumabCapecitabineCyclophosphamideDoxorubicinFluorouracilLeucovorinOxaliplatinPaclitaxelVaccines